ArticleThe EMBO journal2011
Linking the branchpoint helix to a newly found receptor allows lariat formation by a group II intron.
Article in The EMBO journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Protein-free catalysis of DNA hydrolysis and self-integration by a ribozyme.Nucleic acids research · 2025Article
- Group II Introns: Flexibility and Repurposing.Frontiers in molecular biosciences · 2022Article
- Transitions between the steps of forward and reverse splicing of group IIC introns.RNA (New York, N.Y.) · 2020Article
- Article
- Article
- Structural Insights into the Mechanism of Group II Intron Splicing.Trends in biochemical sciences · 2017Review
- Activating the branch-forming splicing pathway by reengineering the ribozyme component of a natural group II intron.RNA (New York, N.Y.) · 2016Article
- Mobile Bacterial Group II Introns at the Crux of Eukaryotic Evolution.Microbiology spectrum · 2015Review
- Group II intron lariat: Structural insights into the spliceosome.RNA biology · 2015Review
- Article
- Origin of spliceosomal introns and alternative splicing.Cold Spring Harbor perspectives in biology · 2014Article
- Visualizing the ai5γ group IIB intron.Nucleic acids research · 2014Article
- Now on display: a gallery of group II intron structures at different stages of catalysis.Mobile DNA · 2013Article
- The brace for a growing scaffold: Mss116 protein promotes RNA folding by stabilizing an early assembly intermediate.Journal of molecular biology · 2012Article
- Structure of the yeast U2/U6 snRNA complex.RNA (New York, N.Y.) · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Like spliceosomal introns, the ribozyme-containing group II introns are excised as branched, lariat structures: a 2'-5' bond is created between the first nucleotide of the intron and an adenosine in domain VI, a component which is missing from available crystal structures of the ribozyme. Comparative sequence analysis, modelling and nucleotide substitutions point to the existence, and probable location, of a specific RNA receptor for the section of domain VI that lies just distal to the branchpoint adenosine. By designing oligonucleotides that tether domain VI to this novel binding site, we have been able to specifically activate lariat formation in an engineered, defective group II ribozyme. The location of the newly identified receptor implies that prior to exon ligation, the distal part of domain VI undergoes a major translocation, which can now be brought under control by the system of anchoring oligonucleotides we have developed. Interestingly, these oligonucleotides, which link the branchpoint helix and the binding site for intron nucleotides 3-4, may be viewed as counterparts of U2-U6 helix III in the spliceosome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.